3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
9
Thoracic
3
Gynecologic
2
Breast
1
Conditions
Breast Neoplasms
69
Triple Negative Breast Neoplasms
32
Ovarian Neoplasms
21
Neoplasm Metastasis
10
Prostatic Neoplasms
8
Pancreatic Neoplasms
7
Fanconi Anemia, Complementation Group D1
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Advanced Breast Cancer
4
Recurrence
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Inflammatory Breast Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian
1
Interventions
pembrolizumab
28
Trastuzumab
16
Paclitaxel
14
Docetaxel
12
Cyclophosphamide
11
Capecitabine
11
Nivolumab
9
fludarabine
7
Carboplatin
7
Oxaliplatin
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
Specimen Handling
5
Leucovorin
5
Irinotecan
5
Injections
5
Gemcitabine
5
Fluorouracil
5
Bevacizumab
5
atezolizumab
4
aldesleukin
4
Taxes
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Drug Therapy
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
zanidatamab
3
veliparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
olaparib
×
Breast
×
Clear all
NCT02734004
2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2
Active not recruiting
264 enrolled
32 charts